A report from sustainability non-profit Changing Markets has criticized what it characterizes as uncontrolled pollution from pharmaceuticals manufacturers in India.
The group investigated one of the world’s largest “bulk drug” manufacturing hubs in Hyderabad, which provides large volumes of medications for markets in the USA and in Europe.
Changing markets was asked to conduct a follow up report after negative coverage in 2016 of the environmental impact of companies in the area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze